Business
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and Smallpox ATLANTA, GA - June 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq:...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and Smallpox","length":178,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - June 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced that it has received positive Scientific Advice (SA) from the European Medicines Agency (EMA) for GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for the prevention of Mpox and smallpox. The SA supports the suitability of GeoVax's clinical and nonclinical development strategy. This feedback from EMA provides clear regulatory alignment and enables an efficient pathway toward potential approval, eliminating multiple development steps commonly required for vaccines.","length":693,"tagName":"p"},{"type":"text","content":"The EMA's Committee for Medicinal Products for Human Use (CHMP) confirmed the adequacy of GeoVax's proposed non-clinical immuno-bridging and toxicity studies to support progression to a Phase 3 study and MAA, assuming no unexpected findings occur. They also confirmed Phase 1 and Phase 2 trials could be omitted and that a single, robustly designed Phase 3 immuno-bridging trial against the approved MVA vaccine (Imvanex), if successful, would be sufficient to support an MAA for GEO-MVA via the centralized procedure. The CHMP also agreed with the Company's proposed immunogenicity endpoints in order to demonstrate non-inferiority. GeoVax believes this guidance represents a potentially significant acceleration in the regulatory approval timeline.","length":762,"tagName":"p"},{"type":"text","content":""This positive guidance from EMA represents a major miles...